Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of “Hold” from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $52.00.

OMCL has been the topic of a number of recent research reports. Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Bank of America reaffirmed a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. JPMorgan Chase & Co. boosted their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Wells Fargo & Company raised their target price on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Finally, StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th.

Omnicell Price Performance

NASDAQ:OMCL opened at $45.32 on Friday. The company has a market capitalization of $2.10 billion, a P/E ratio of -116.20, a P/E/G ratio of 34.96 and a beta of 0.78. The business has a fifty day simple moving average of $46.17 and a two-hundred day simple moving average of $40.47. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74.

Insider Activity at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omnicell

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its stake in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares in the last quarter. 1620 Investment Advisors Inc. lifted its holdings in shares of Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Omnicell in the 2nd quarter valued at $104,000. Summit Global Investments bought a new position in shares of Omnicell during the 3rd quarter valued at $221,000. Finally, QRG Capital Management Inc. purchased a new position in Omnicell in the 3rd quarter worth $231,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.